New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
14:25 EDTQGEN, QGEN, NSPH, NSPH, ILMN, ILMN, HOLX, HOLX, BRKR, BRKR, BDX, BDX, ABT, ABT, TMO, TMOLeerink analyst/industry conference call on June 26 is now 2 pm
Life Science Tools & Diagnostics Analyst Leonard discusses trends and controversies in molecular diagnostics on an Analyst/Industry conference call. Relevant companies ABT, BDX, BRKR, HOLX, ILMN, NSPH, QGEN and TMO may be included on the Analyst/Industry conference call to be held on June 26 at 2 pm.
News For QGEN;NSPH;ILMN;HOLX;BRKR;BDX;ABT;TMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
12:01 EDTBDXBecton Dickinson price target raised to $167 from $160 at Piper Jaffray
Subscribe for More Information
07:41 EDTTMO, ABTEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
10:16 EDTTMOHigh option volume stocks
High option volume stocks: NSAM ALU CJES BIG CMRX ERIC NTAP TMO KN CIG
09:06 EDTABTAbbott and Sekisui announce collaboration for coagulation testing
Abbott and Sekisui announce an agreement to offer coagulation testing solutions for laboratories worldwide. Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots. Under the agreement, Abbott will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in the United States, Europe and other regions that recognize CE Mark.
April 7, 2015
11:56 EDTNSPHNanosphere announces reverse split of common stock
Subscribe for More Information
11:42 EDTNSPHNanosphere solicited by Navy for Verigene RV+ test contract
Subscribe for More Information
07:21 EDTILMNIllumina buy-side expectations may be too high, says UBS
Subscribe for More Information
April 6, 2015
13:32 EDTBDXBecton Dickinson, Breakout Labs form strategic relationship
Breakout Labs, Peter Thielís philanthropic revolving fund for early-stage science and technology companies, and BD announced that they have established a strategic relationship to provide additional grant funding and professional expertise to qualifying Breakout Labs portfolio companies. Under the terms of the agreement, BD will periodically review Breakout Labsí portfolio for companies developing cutting-edge technologies that are relevant to the strategic interests of BDís Medical and Life Sciences business segments. Breakout Labs companies selected to participate will be given an unrestricted grant of up to $25,000 from BD, and assigned a business mentor responsible for providing guidance and connections to subject matter experts throughout the company.
10:02 EDTBRKROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:22 EDTTMO, QGEN, ILMNBofA/Merrill life sciences analysts hold an analyst/industry conference call
Subscribe for More Information
08:02 EDTBRKRBruker upgraded to Outperform with $24 price target at Leerink
Leerink upgraded Bruker to Outperform from Market Perform saying it sees share upside from the company's operational improvements and better competitive position in nuclear magnetic resonance instruments. The firm raised its price target for shares to $24 from $21.
05:42 EDTBRKRBruker upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information
April 5, 2015
12:47 EDTBRKRBruker gets FDA clearance for 2nd expanded claim for MALDI Biotyper CA System
Bruker announced that it has received 510(k) clearance from the US Food and Drug Administration for library and methods expansion for the MALDI Biotyper CA System, sold in the United States for clinical microbiology. In November 2013, Bruker received FDA 510(k) clearance for a first claim for the MALDI Biotyper CA System, an IVD solution, which included Brukerís global market leading MALDI Biotyper instrumentation; software; a library of 40 aerobic Gram negative bacterial species or species groups, covering 100 clinically relevant species; in vitro diagnostic reagents; and standard operating procedures. The recent clearance of a second, expanded claim now adds 170 species and species groups, representing 180 clinically-relevant species of aerobic Gram positive, fastidious Gram negatives, Enterobacteriaceae, anaerobic bacteria and yeasts. In addition, customers will have additional specimen preparation options to further optimize workflows. As a result of the latest 510(k) clearance, the MALDI Biotyper CA System can now in total identify 210 species or species groups, covering 280 clinically relevant bacteria and yeast species, and representing more than 98% of the typical bacterial identification workflow of clinical microbiology laboratories.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use